Glioblastoma, IDH-wildtype Clinical Trial
Official title:
Improving Personalised Glioblastoma Care by Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence Approaches
The study aims at: 1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis and defining key life/environmental elements, to guide AI-driven personalised treatments and ensure improved care and QoL of glioblastoma patients. 2. To deepen glioblastoma knowledge through the study of glioblastoma stem cell cultures and to assess the sensitivity of glioblastoma stem cell cultures to a number of chemotherapeutics in different experimental conditions. 3. To create a comprehensive, stakeholder-generated guidelines for the ethical use of patient data for artificial intelligence-assisted prediction systems in glioblastoma, including an online, easily accessible patient information brochure to increase patient empowerment in the field.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06160596 -
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
|
||
| Recruiting |
NCT05879250 -
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT04945148 -
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
|
Phase 2 | |
| Not yet recruiting |
NCT05842746 -
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT06419946 -
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
|
Phase 3 | |
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT06418113 -
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT05326334 -
THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
|
||
| Recruiting |
NCT05375318 -
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
|
||
| Not yet recruiting |
NCT06359379 -
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
|
Phase 2 | |
| Recruiting |
NCT06095375 -
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
|
Phase 1 | |
| Recruiting |
NCT05879367 -
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT05759195 -
Biomolecular Analysis for Predicting Response to Regorafenib
|
N/A | |
| Recruiting |
NCT06273176 -
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
|
||
| Recruiting |
NCT06283927 -
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
|
||
| Recruiting |
NCT06146738 -
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
|
||
| Recruiting |
NCT06146725 -
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
|
||
| Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|